Press Releases

Year

November 30, 2021

Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

– Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated – – Phase 2/3 Chronic Spontaneous Urticaria trial of subcutaneous lirentelimab to begin in mid 2022 – – Phase 2 Asthma trial of subcutaneous lirentelimab to begin in Q4 2022 – – Additional indications planned in 2023 – REDWOOD

November 8, 2021

Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results

REDWOOD CITY, Calif. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the third

October 25, 2021

Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation

– Study shows 45% (181/405) of patients with moderate-to-severe unexplained gastrointestinal symptoms who underwent upper endoscopy with biopsy met the histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) – – Presentation selected for “ACG Presidential Poster

October 24, 2021

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting

REDWOOD CITY, Calif. , Oct. 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of six poster presentations at the upcoming

August 9, 2021

Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results

REDWOOD CITY, Calif. , Aug. 09, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the

June 7, 2021

Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)

-- Results from both clinical trials expected in the fourth quarter of 2021 -- -- CMO Dr. Henrik Rasmussen to retire; Dr. Craig Paterson , SVP of Clinical Development and Medical Affairs, promoted to CMO -- REDWOOD CITY, Calif. , June 07, 2021 (GLOBE NEWSWIRE) -- Allakos Inc.

May 24, 2021

New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms

45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) REDWOOD CITY, Calif. , May 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”)

May 10, 2021

Allakos Reports First Quarter 2021 Financial Results and Provides Business Update

REDWOOD CITY, Calif. , May 10, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2021

April 19, 2021

Allakos Appoints Baird Radford as Chief Financial Officer

REDWOOD CITY, Calif. , April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird Radford has been appointed Chief

March 30, 2021

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting

REDWOOD CITY, Calif. , March 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptance of two oral and five poster

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 11

Investors

Press Releases

(Common Stock)

Investor Toolkit